

IN THE CLAIMS:

1-24. (Canceled)

25. (Currently Amended) A pharmaceutical composition for the treatment of female hormonal deficiencies, said composition comprising:

- a therapeutically effective amount of an estrogenic compound;
- a therapeutically effective amount of a non-aromatizing androgenic compound;
- a therapeutically effective amount of a progestin compound; and
- a pharmaceutically acceptable carrier.

26. (Canceled)

27. (Original) The pharmaceutical composition of Claim 25, wherein the non-aromatizing androgenic compound is selected from the group consisting of oxandrolone, oxymetholone, stanozolol, danazol, pharmaceutically acceptable esters and salts thereof, and combinations of any of the foregoing.

28. (Canceled)

29. (New) The pharmaceutical composition of Claim 25, wherein the estrogenic compound is selected from the group consisting of estrone, 17 α -estradiol, 17 β -estradiol, equilin, 17 α -dihydroequilin, 17 β -dihydroequilin, equilenin, 17 α -dihydroequilenin, 17 β -dihydroequilenin, $\Delta^{8,9}$ -dehydroestrone, 17 α - $\Delta^{8,9}$ -dehydroestradiol, 17 β - $\Delta^{8,9}$ -dehydroestradiol, ethynodiol diacetate, estradiol valerate, 6-OH equilenin, 6-OH 17 α -dihydroequilenin, 6-OH 17 β -dihydroequilenin, and mixtures, conjugates and salts thereof.

30. (New) A pharmaceutical composition for the treatment of female hormonal deficiencies, said composition comprising:

- a therapeutically effective amount of 17 β -estradiol;
- a therapeutically effective amount of a non-aromatizing androgenic compound, wherein the non-aromatizing androgenic compound is selected from the group consisting of

oxandrolone, oxymetholone, stanozolol, danazol, pharmaceutically acceptable esters and salts thereof, and combinations of any of the foregoing; and
a pharmaceutically acceptable carrier.

31. (New) The composition of Claim 30, further comprising a therapeutically effective amount of a progestin compound.

32. (New) A pharmaceutical composition for the treatment of female hormonal deficiencies a mixture of estrogenic compounds, wherein said mixture consists essentially of:

B1
salts of conjugated estrone, conjugated equilin, conjugated $\Delta^{8,9}$ -dehydroestrone, conjugated 17 α -estradiol, conjugated 17 β -dihydroequilin, conjugated 17 α -dihydroequilin, conjugated 17 β -estradiol, conjugated equilenin, conjugated 17 α -dihydroequilenin, and conjugated 17 β -dihydroequilenin; and

a therapeutically effective amount of a non-aromatizing androgenic compound, wherein the non-aromatizing androgenic compound is selected from the group consisting of oxandrolone, oxymetholone, stanozolol, danazol, pharmaceutically acceptable esters and salts thereof, and combinations of any of the foregoing.

33. (New) The pharmaceutical composition of Claim 32, wherein the pharmaceutical composition further comprises an estrogenic compound is selected from the group consisting of estrone, 17 α -estradiol, 17 β -estradiol, equilin, 17 α -dihydroequilin, 17 β -dihydroequilin, equilenin, 17 α -dihydroequilenin, 17 β -dihydroequilenin, $\Delta^{8,9}$ -dehydroestrone, 17 α - $\Delta^{8,9}$ -dehydroestradiol, 17 β - $\Delta^{8,9}$ -dehydroestradiol, ethinyl estradiol, estradiol valerate, 6-OH equilenin, 6-OH 17 α -dihydroequilenin, 6-OH 17 β -dihydroequilenin, and mixtures, conjugates and salts thereof.
